Pharmacokinetics and the bystander effect in CD：：UPRT/5-FC bi-gene therapy of glioma

• Published in: Chinese medical journal Vol. 122; no. 11; pp. 1267 - 1272
• Main Authors: Shi, De-zhi, Hu, Wei-xing, Li, Li-xin, Chen, Gong, Wei, Dong, Gu, Pei-yuan
• Format: Journal Article
• Language: English
• Published: China Department of Neurosurgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China 05.06.2009
• Subjects: Animals; Antimetabolites - pharmacokinetics; Antimetabolites - therapeutic use; Cell Line; Cytosine Deaminase - genetics; Cytosine Deaminase - physiology; Flucytosine - pharmacokinetics; Flucytosine - therapeutic use; Genetic Therapy - methods; Glioma - drug therapy; Glioma - therapy; Humans; Magnetic Resonance Imaging; Male; Pentosyltransferases - genetics; Pentosyltransferases - physiology; Rats; Rats, Sprague-Dawley; UPRT/5-FC双基因; 临床试验; 脑胶质瘤; 药物动力学; bystander effect; pharmacokinetics; glioma; cytosine deaminase; magnetic resonance spectroscopy; uracil phosphoribosyltransferase

Background Cytosine deaminase （CD） converts 5-fluorocytosine （5-FC） to 5-fluorouracil （5-FU） in CD/5-FC gene therapy, 5-FU will be mostly converted into nontoxic 13-alanine without uracil phosphoribosyltransferase （UPRT）. UPRT catalyzes the conversion of 5-FU to 5-fluorouridine monophosphate, which...